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Abstract
We studied the effect of trans-4-hydroxy-2-nonenal on the wild-type human adenylosuccinate lyase and on the enzyme
from a patient compound-heterozygous for two missense mutations (P75A/D397Y; McKusick 103050.0003/103050.0004).
Both the enzymes were inhibited by 10^50 WM trans-4-hydroxy-2-nonenal in a concentration-dependent manner by means of
a mixed-type co-operative mechanism. A significantly stronger inhibition was noticed in the presence of the defective enzyme.
Nonanal and trans-2,3-nonenal inhibited the enzymes to a less extent and at about 10-times higher concentrations.
Hydroxylamine reversed the inhibition by trans-4-hydroxy-2-nonenal, trans-2,3-nonenal or nonanal in the case of the wild-
type enzyme, but it was ineffective to reverse the inhibition by trans-4-hydroxy-2-nonenal on the defective enzyme.
Dithiothreitol slightly decreased the inhibition exerted by trans-4-hydroxy-2-nonenal on both the wild-type and the defective
adenylosuccinate lyase, while it did not produce practically any change in the presence of trans-2,3-nonenal or
nonanal. ß 2000 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Adenylosuccinate lyase (adenylosuccinase; EC
4.3.2.2) is a tetrameric enzyme that catalyzes two
distinct reactions in the purine synthesis, both involv-
ing the removal of fumarate: the conversion of suc-
cinylaminoimidazole carboxamide (SAICA) ribotide
into aminoimidazole carboxamide ribotide along the
de novo pathway, and the formation of AMP from
adenylosuccinate (S-AMP) in the conversion of IMP
into adenine nucleotides [1,2]. The catalysis follows
order uni^bi kinetics with fumarate leaving the en-
zyme before the nucleotides. The reactions are
thought to involve a L-elimination mechanism, in
which deprotonation of CL and cleavage of N^CK
in the substrate occur in a concerted manner. Little
information is available on the role of enzymic ami-
no acids in the catalysis. Studies on the enzymes
from rabbit muscle and Bacillus subtilis suggest that
Arg-60, His-61, and Arg-112 (the numbering is based
on the human enzyme sequence reported in reference
[3], which is shorter than that recently published on
EMBL data base, accession number X65867) are lo-
cated within the substrate-binding site [4,5], while
His-134 acts as a general base accepting the proton
from CL [6]. The protection of the enzyme by dithio-
threitol and EDTA suggests that thiol groups on the
protein are essential for activity [1,2].
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Decreased levels of adenylosuccinase activity have
been reported in approximately 40 patients showing
psychomotor retardation [7^13]. A remarkable fea-
ture of the disease is the high incidence of autistic
symptoms. The prognosis for survival of profoundly
retarded patient is poor. The defect is transmitted as
an autosomic recessive trait and characterized by the
accumulation in body £uids of two normally unde-
tectable compounds, SAICA riboside and succinyla-
denosine, that are the dephosphorylation products
of the two substrates of the enzyme. About one-third
of the patients has been analyzed at the gene level
[13]. Most of the reported data refer to the defective
enzymes from a Moroccan family (McKusick
103050.0001) and an Italian family (McKusick
103050.0003/103050.0004). In the former case, a sin-
gle T-to-C transition in the adenylosuccinase gene
leading to a Ser-413 to Pro substitution segregates
with mental retardation [3]. In the case of the Italian
family, the patient is compound-heterozygous for
two missense mutations on di¡erent alleles [14]: a
C-to-G transversion corresponding to a Pro-75 to
Ala substitution and a G-to-T transversion corre-
sponding to an Asp-397 to Tyr substitution (P75A/
D397Y adenylosuccinase). In both kindred, the
defective enzymes show a great heat lability and
an increased sensitivity to guanadinium HCl and
urea, without changing in the kinetic parameters
[3,9].
It has been reported [7,15] that adenylosuccinase
de¢ciency in a minority of patients is more severe in
liver, kidney, and lymphocytes than in skeletal
muscle and erythrocytes. Since the available data
seem to exclude the presence of tissue-speci¢c iso-
zymes [3,14], this may imply that yet unde¢ned reg-
ulatory mechanisms play a role in controlling adeny-
losuccinase level within certain cell types. The tissue
identity of the enzyme also opens the possibility to
get generalizable results on enzyme properties with
enzyme preparations from di¡erent tissues. We re-
port here that adenylosuccinase is speci¢cally inhib-
ited by micromolar concentrations of trans-4-hy-
droxy-2-nonenal (HNE), a major product of
membrane peroxidation, which is believed to cause
some of the tissue damage that occurs in vivo under
conditions of oxidative stress [16] and plays an im-
portant role in diseases of central and peripheral
nervous tissue [17^19].
2. Materials and methods
Nonanal, trans-2,3-nonenal, hydroxylamine, and
dithiothreitol were supplied by Aldrich. HNE was
prepared by the acid treatment (1 mM HCl) of
trans-4-hydroxy-2-nonenal diethylacetal that was
generously provided by Dr. H. Zollner (University
of Graz). The concentration of HNE was determined
spectrophotometrically at 224 nm by assuming a mo-
lar absorptivity of 13 750 M31 [16]. Other reagents
were high purity commercial samples from Sigma.
Crude preparations of wild-type (1.6 IU/g protein)
and P75A/D397Y (1.2 IU/g protein) erythrocyte ad-
enylosuccinase were obtained from healthy subjects
and from patient with adenylosuccinase de¢ciency by
step-wise precipitation in ammonium sulfate [9]. Pu-
ri¢ed preparations of erythrocyte adenylosuccinase
(700 IU/g protein) were obtained from healthy vol-
unteers by using the procedure described in reference
[1] with minor modi¢cations. Prior to exposure of the
enzyme to aldehydes, dithiothreitol was removed by
exhaustive dialysis. Adenylosuccinase activity was
determined by following the conversion of S-AMP
into AMP spectrophotometrically at 282 nm. En-
zyme activity was linear under all conditions tested
over the time assayed.
All experiments were performed in 10 mM Tris-
HCl, 10 mM KCl, 2 mM EDTA, pH 7.4 at 37‡C,
unless otherwise stated. Mathematical models were
¢tted to the experimental data by a non-linear regres-
sion program [20]. Measurements were performed in
triplicate. The standard deviation of control values
was estimated from independent series of measure-
ments performed with enzyme preparations from
three di¡erent healthy subjects.
3. Results
To test the e¡ect of HNE on the enzyme activity,
adenylosuccinase (¢nal activities between 0.5 and
4 IU/l) was incubated with various concentrations
of HNE (0^500 WM) for 1^120 min at 37‡C. The
activity was measured by adding 0.01 volumes of
10 mM S-AMP to samples withdrawn from the in-
cubation mixture. As shown in Fig. 1, the enzyme
was inhibited by micromolar [HNE] in a concentra-
tion-dependent manner. The inhibition was achieved
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rapidly (within 1-min incubation). No further
changes in enzyme activity were observed over the
time interval pertinent to the experiments. The frac-
tional decrease in adenylosuccinase activity was in-
dependent of enzyme concentration and purity under
the employed experimental conditions. We did not
observe signi¢cant changes in the shape of the inhi-
bition titration curve by using enzyme preparations
from di¡erent healthy subjects. In contrast,
P75A/D397Y adenylosuccinase showed greater sensi-
tivity to HNE inhibition than wild-type enzyme. The
inhibition was reversed by diluting the enzyme^HNE
mixture. We also attempted to remove the inhibitor
by dialysis. However, because of the slow and limited
di¡usion of HNE through the membrane (data not
shown), the enzyme was only partially reactivated by
this way.
We explored the e¡ect, on the enzymatic catalysis,
of aldehydes that are di¡erent from HNE by lack of
the hydroxy group (trans-2,3-nonenal) and by lack of
both the hydroxy group and the alpha,beta-double
bond (nonanal). As shown in Fig. 1, trans-2,3-none-
nal and nonanal inhibited enzyme activity to a less
extent and at about ten-times higher concentrations.
Nonanal exerted the smallest inhibitory e¡ect. Addi-
tion of 250 WM hydroxylamine, which is thought to
form non-dissociable oxime derivatives with the al-
dehydes [21], reversed at least half of the inhibition
exerted by HNE or trans-2,3-nonenal and completely
the inhibition by nonanal on the wild-type enzyme
(Table 1). Hydroxylamine (250 WM) reversed the in-
hibition of the P75A/D397Y adenylosuccinase by
trans-2,3-nonenal or nonanal in the same extent as
in the experiments with the wild-type enzyme, but it
was ine¡ective against HNE. Dithiothreitol (500 WM)
reduced the inhibition by 20 WM HNE on both wild-
type and P75A/D397Y adenylosuccinase, while it did
not produce any change in the presence of 200 WM
trans-2,3-nonenal or 200 WM nonanal. Higher con-
centrations of hydroxylamine and/or dithiothreitol
were inhibitory (data not shown).
The e¡ect of substrate addition to the enzyme^in-
Fig. 1. Inhibition of adenylosuccinase activity by aldehydes
(ab, HNE; OR, trans-2,3-nonenal; EF, nonanal). Enzyme ac-
tivities in the absence of aldehydes were scaled to 100%. The
concentration of S-AMP was 100 WM. Open symbols refer to
wild-type adenylosuccinase, while closed symbols refer to P75A/
D397Y adenylosuccinase. All tests were performed in triplicate
and expressed as mean values. Error bars indicate one standard
deviation from the mean of independent tests performed with
enzyme preparations from three di¡erent healthy subjects. All
other conditions were as described in the text.
Table 1
E¡ect of hydroxylamine (HA) and dithiothreitol (DTT) on the inhibition exerted by HNE, trans-2,3-nonenal, and nonanal
Aldehydes
None HNE (20 WM) trans-2,3-Nonenal (200 WM) Nonanal (200 WM)
None 100.0 72.4 þ 2.2 75.3 þ 1.4 84.0 þ 2.1
100.0 49.1 71.5 84.6
0.25 mM HA 99.7 þ 0.7 90.1 þ 1.9 87.5 þ 8.7 99.3 þ 1.0
96.5 48.7 81.6 93.4
0.50 mM DTT 99.2 þ 1.4 83.5 þ 6.0 74.9 þ 1.6 84.0 þ 2.1
98.7 54.3 71.7 84.2
0.25 mM HA+0.50 mM DTT 101.5 þ 0.5 93.5 þ 2.8 88.3 þ 8.5 98.2 þ 0.8
100.9 52.2 82.9 93.6
Adenylosuccinase activity is expressed as percentage of the initial activity. Bold numbers are means þ S.D. of independent tests per-
formed with enzyme preparations from three di¡erent healthy subjects. Italic numbers refer to P75A/D397Y enzyme. all other condi-
tions were as described in Fig. 1.
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hibitor mixture was tested by varying S-AMP con-
centration at di¡erent ¢xed concentrations of HNE.
Both wild-type and P75A/D397Y adenylosuccinase
showed Michaelian relations between steady-state ve-
locity and S-AMP concentration in the absence of
HNE. Substrate inhibition was observed at relatively
high [S-AMP] only in presence of HNE, as shown in
the double reciprocal plots reported in Fig. 2. Re-
plots of slope/Km and ordinate intercept of the ex-
trapolated linear part of the curves versus [HNE]
revealed a co-operative mixed-type inhibition by the
hydroxyalkenal (Fig. 3). Table 2 reports the kinetic
constants of the enzymatic reaction calculated by
using Hill’s algorithm under rapid equilibrium as-
sumption [22]. The kinetic analysis is consistent
with the view that HNE reacts with both the free
enzyme and the enzyme^substrate complex (though
with di¡erent a⁄nity), leading to kinetically ine¡ec-
tive enzyme species. The a⁄nity of HNE for P75A/
D397Y adenylosuccinase is signi¢cantly higher than
that for the wild-type enzyme, in good agreement
with the results obtained in the inhibition titration
experiments (Fig. 1).
4. Discussion
Lipid peroxidation is always combined with the
formation of reactive aldehydes [23,24], HNE being
a major aldehyde produced in vivo during the per-
oxidation of polyunsaturated fatty acids [16]. This
Fig. 2. Double reciprocal plot of speci¢c velocity (v/Vmax)
against [S-AMP] at di¡erent ¢xed concentrations of HNE. The
concentrations of HNE were: ab, none; 78, 25 WM; OR,
35 WM; EF, 40 WM; P, 50 WM. Open symbols refer to wild-
type adenylosuccinase, while closed symbols refer to P75A/
D397Y adenylosuccinase. All other conditions were as described
in Fig. 1.
Fig. 3. Ordinate-intercept and slope/Km replots. Each curve rep-
resents data from a family of reciprocal plots obtained as
shown in Fig. 2. The experiments were performed by using
highly puri¢ed wild-type adenylosuccinase (U) as well as crude
enzyme preparations (a, wild-type; b, P75A/D397Y). Error
bars indicate one standard deviation from the mean of inde-
pendent tests performed with enzyme preparations from three
di¡erent healthy subjects.
Table 2
Kinetic constants of the enzymatic reaction catalyzed by adenylosuccinase
Reaction Equation Parameter Adenylosuccinase
Wild-type P75A/D397Y
E SKm ES! E P Vmax
v
 KmS  1 Km (WM) 5 þ 2 6.1
E nIK i EIn slopeKm  1
I
K i
 n
Ki (WM) 45 þ 7 34
n 3 þ 1 2.1
ESmIaK i ESIm intercept  1 I aK i
 m
aKi (WM) 37 þ 4 28
m 2.3 þ 0.2 2.9
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compound has a high biological activity and exhibits
a number of cytotoxic, mutagenic, and genotoxic ef-
fects [16]. It is considered that at least some of the
damage observed in free radical pathology is medi-
ated by HNE and other aldehydes, which may act as
‘second toxic messenger’ of the primary free radical
event. The hypothetic sequence free radicals^lipid
peroxidation^aldehyde formation^damage was pro-
posed by Esterbauer et al. [16]. The most cell types
and organs possess high capacities for removal of
HNE by di¡erent metabolic pathways to prevent
HNE accumulation and toxic consequences [25^27].
Nevertheless, HNE concentration is signi¢cantly in-
creased in plasma, various organs, and cell types
under certain conditions of oxidative stress [28,29].
Under those conditions, HNE concentrations up to
the micromolar range were measured, e.g. 6 WM in
reperfused small intestine [30,31]. Of special impor-
tance is the subcellular compartmentation of HNE
and other aldehydic lipid peroxidation products. It
is assumed that in hydrophobic regions of mem-
branes much higher HNE concentrations occur.
For membranes in isolated peroxidized microsomes
even a HNE concentration of approximately 4.5 mM
was calculated [32].
HNE binding to proteins is of great importance
concerning the pathophysiological consequences of
free radical-initiated reactions. The I50-values for
HNE inhibition have been reported for several en-
zymes [21,33^36]: glucose-6-phosphatase (70 WM),
adenylate cyclase (2.7 WM), 5P-nucleotidase (s 5
mM), DNA polymerase K (370 WM), DNA polymer-
ase L (290 WM), and Na- K-ATPase (120 WM).
The binding of HNE to glucose-6-phosphate dehy-
drogenase and glyceraldehyde-3-phosphate dehydro-
genase results to irreversible enzyme inactivation
[37,38]. The chemical mechanism of alkenal and hy-
droxyalkenal binding to proteins have been studied
intensively by the group of Uchida and Stadtman
[38^42]. The ¢ndings of these authors may have im-
portant implications for the accumulation of proteins
modi¢ed by aldehydes in vivo [43], a process that is
believed to be involved in age- and disease-related
impairment of cellular function [44,45].
In our experiments a reversible inhibition of ad-
enylosuccinase by HNE was observed. The mutated
enzyme was more sensitive in comparison to the
wild-type. The 50% inhibitions were reached with
about 17 and 32 WM, respectively. The binding of
HNE to adenylosuccinase was characterized by using
analogs (trans-2,3-nonenal, nonanal) lacking in some
of the functional groups as well as by adding speci¢c
reagents. We found that the lack of the hydroxy
group greatly reduced the a⁄nity of the inhibitor
for the enzymes. The inhibitory e¡ect was further
reduced removing the alpha,beta-double bond. The
result obtained in the presence of hydroxylamine (see
Table 1) could be taken as evidence that the carbonyl
group of nonanal was involved in the binding, but it
did not exclude more complex mechanisms in the
case of HNE and trans-2,3-nonenal. Indeed, it could
be hypothesized that these alkenals bind to the pro-
tein through a reaction involving the alpha,beta-dou-
ble bond, in which the carbonyl function is pre-
served, and that the reversal of inhibition by
hydroxylamine was due to electrostatic and/or steric
hindrance of the oxime group. This proposal was in
line with the ¢nding that, when P75A/D397Y adeny-
losuccinase was used instead of the wild-type en-
zyme, hydroxylamine reversed the inhibition by
trans-2,3-nonenal or nonanal, but it was ine¡ective
against HNE. Experiments with dithiothreitol gave
indirect evidence for a thio^ether linkage between
HNE and the enzyme. The addition of dithiothreitol
reduced the enzyme inhibition by HNE, but it did
not reduce the enzyme inhibition by trans-2,3-none-
nal or nonanal.
Adenylosuccinase de¢ciency results in mental re-
tardation and some further clinical symptoms, which
lead in total to a severe disease not only of the cen-
tral and peripheral nervous system. The pathogenesis
of the symptoms is still debated, since de¢ciency of
metabolites which are normally formed distally from
the enzyme defect, as well as accumulation of inter-
mediates proximally thereof, could have deleterious
e¡ects. [8,9]. Our experiments on inhibition of adeny-
losuccinase activity by HNE, which is much stronger
for the point mutated enzyme, suggest that free rad-
icals and lipid peroxidation products may be respon-
sible of the impairment of enzyme activity and, at
least in part, of the subsequent tissue damage. The
importance of free radical-initiated changes for dif-
ferent diseases and disturbances of the central and
peripheral nervous systems was demonstrated for
stroke, Alzheimer’s disease, traumatic spinal cord in-
jury, cerebral circulatory insu⁄ciency, Huntington’s
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disease, systemic amyloidosis and others [17^19,46].
Our hypothesis is supported by the high frequency in
succinylpurinemic autism of symptoms, which are
connected with increased formation of free radicals
and lipid peroxidation products, such as convulsions,
muscle wasting, and recurrent infections of the upper
respiratory tract [8,12].
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